Form 4: AbbVie Director Glenn F. Tilton Reports Changes in Beneficial Ownership

Director Glenn F. Tilton reports acquisition of restricted stock units and disposition of common stock.

Summary

• On May 3, 2024, AbbVie Director Glenn F. Tilton reported changes in beneficial ownership of AbbVie Inc. stock.
• Tilton acquired 1,322 shares of common stock through restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program.
• These restricted stock units will be paid in shares of AbbVie common stock upon separation from service, death, or a change in control.
• Tilton also reported the disposition of 350 shares of common stock held indirectly by his wife, for which he disclaims beneficial ownership.
• Following these transactions, Tilton directly owns 50,361 shares of AbbVie common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a director. The acquisition of restricted stock units is a positive sign, but the disposition of shares (even if disclaimed) introduces a slight negative element.

Positives

• The acquisition of restricted stock units suggests continued alignment of the director's interests with the company's long-term performance.

Negatives

• The disposition of 350 shares, while attributed to his wife and disclaimed by Tilton, could be perceived negatively by some investors.

Risks

• The value of the restricted stock units is tied to AbbVie's stock price, making them subject to market risk.
• Changes in control, as defined in the Program, could trigger the payout of these units, potentially impacting the company's cash flow.

Future Outlook

The document does not contain specific forward-looking statements regarding AbbVie's future performance.

Industry Context

This filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It's common for directors to receive stock-based compensation as part of their overall remuneration.

Comparison to Industry Standards

• Stock ownership and trading activity by directors are common and expected in publicly traded companies like AbbVie.
• Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also have similar insider trading reporting requirements.
• The AbbVie Amended and Restated 2013 Incentive Stock Program is similar to equity compensation plans offered by other large pharmaceutical companies to align executive and director interests with shareholder value.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding the director's stake in the company.
• The stock transactions could influence investor sentiment, although the impact is likely to be minimal given the relatively small number of shares involved.

Key Dates